Sapphiros develops diagnostic platforms, sample collection devices, next-generation diagnostics, and extreme-volume manufacturing capabilities aimed at expanding access to high-quality testing. The company is advancing a proprietary molecular diagnostics platform designed to deliver laboratory-quality results via a simple, automated workflow in point-of-care and decentralized settings. Its program work includes a novel closed blood collection tube to reduce blood-borne contamination risk and a partnership to integrate Satio's capillary blood collection system to enable phlebotomist-free sampling. Sapphiros recently secured a $12.4 million BARDA award under the RRPV to support a 24-month base development period for disposable molecular testing for blood-based pathogens, and this is its second BARDA agreement following prior funding to develop an over-the-counter digital antigen test. The company is privately backed by KKR and Neoenta and is based in Boston.

Total raised

$42M

Funding rounds

2

Latest round

Grant

Latest activity

Jul 2026